Holen Sie sich die Stockscreener-App
237.05
1.04%
-2.48
Schlusskurs vom Vortag:
$239.53
Offen:
$240.44
24-Stunden-Volumen:
977.42K
Relative Volume:
0.81
Marktkapitalisierung:
$38.54B
Einnahmen:
$2.75B
Nettoeinkommen (Verlust:
$714.14M
KGV:
54.75
EPS:
4.33
Netto-Cashflow:
$1.09B
1W Leistung:
+0.24%
1M Leistung:
+9.22%
6M Leistung:
+0.87%
1J Leistung:
+16.25%
1-Tages-Spanne:
$236.20
$241.41
1-Wochen-Bereich:
$231.79
$242.00
52-Wochen-Spanne:
$170.25
$258.93
Veeva Systems Inc Stock (VEEV) Company Profile
Firmenname
Veeva Systems Inc
Sektor
Branche
Telefon
925-452-6500
Adresse
4280 HACIENDA DRIVE, PLEASANTON, CA
Vergleichen Sie VEEV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VEEV
Veeva Systems Inc
|
237.05 | 38.54B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
59.19 | 11.13B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
61.37 | 9.87B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
90.40 | 7.83B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
40.01 | 7.04B | 906.14M | -52.62M | 89.62M | -0.3621 |
Veeva Systems Inc Stock (VEEV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-23 | Herabstufung | Goldman | Buy → Sell |
| 2024-12-20 | Eingeleitet | Stephens | Overweight |
| 2024-12-04 | Eingeleitet | Mizuho | Outperform |
| 2024-11-19 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-08 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2024-08-27 | Bestätigt | Citigroup | Buy |
| 2024-07-09 | Eingeleitet | BTIG Research | Buy |
| 2023-10-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-10-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-28 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Truist | Buy → Hold |
| 2023-02-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-04 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-06 | Eingeleitet | Cowen | Market Perform |
| 2022-12-02 | Bestätigt | Needham | Buy |
| 2022-10-31 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-10-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | Goldman | Buy |
| 2022-06-21 | Fortgesetzt | Guggenheim | Buy |
| 2022-03-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2022-01-07 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Fortgesetzt | Stifel | Buy |
| 2021-09-02 | Bestätigt | BofA Securities | Buy |
| 2021-09-02 | Bestätigt | JMP Securities | Mkt Outperform |
| 2021-09-02 | Bestätigt | Needham | Buy |
| 2021-09-02 | Bestätigt | UBS | Neutral |
| 2021-07-21 | Eingeleitet | Cowen | Outperform |
| 2021-03-31 | Hochstufung | UBS | Sell → Neutral |
| 2021-01-07 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2020-12-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-10-14 | Fortgesetzt | UBS | Sell |
| 2020-08-28 | Bestätigt | Needham | Buy |
| 2020-07-23 | Eingeleitet | FBN Securities | Outperform |
| 2020-07-07 | Eingeleitet | Stephens | Overweight |
| 2020-06-08 | Eingeleitet | Citigroup | Buy |
| 2020-05-29 | Bestätigt | Needham | Buy |
| 2020-04-13 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-14 | Eingeleitet | Piper Sandler | Overweight |
| 2020-01-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-11-27 | Bestätigt | Canaccord Genuity | Hold |
| 2019-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-08-28 | Bestätigt | Needham | Buy |
| 2019-06-07 | Eingeleitet | Goldman | Neutral |
| 2019-05-30 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2019-05-24 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-27 | Bestätigt | Needham | Buy |
Alle ansehen
Veeva Systems Inc Aktie (VEEV) Neueste Nachrichten
Veeva Systems (VEEV) Rises But Trails Market: What Investors Should Know - Yahoo Finance
Veeva to Release Fiscal 2026 First Quarter Results on May 28, 2025 | VEEV Stock News - GuruFocus
Veeva to Release Fiscal 2026 First Quarter Results on May 28, 2025 - Yahoo Finance
eClinical Solutions Market Size to Lead USD 40,500 Million by 2034, Growth in the Biopharmaceutical and Pharmaceutical Industry - GlobeNewswire Inc.
Life Sciences Leaders Advance Unified Engagement at Veeva Commer - GuruFocus
Life Sciences Leaders Advance Unified Engagement at Veeva Commercial Summit | VEEV Stock News - GuruFocus
Major Pharma Leaders Join Veeva to Reveal Game-Changing AI Integration for Commercial Operations - Stock Titan
Veeva: Our 2025 Software Pick Just Keeps Winning (NYSE:VEEV) - Seeking Alpha
Connecting Quality and Regulatory for Data-Driven Change Control - Veeva
2024 Veeva Commercial Summit | Veeva - Veeva
June 2026 Options Now Available For Veeva Systems (VEEV) - Nasdaq
Veeva Systems (VEEV) Stock Declines While Market Improves: Some Information for Investors - Yahoo
Investors Heavily Search Veeva Systems Inc. (VEEV): Here is What You Need to Know - MSN
Here's How Much $100 Invested In Veeva Systems 10 Years Ago Would Be Worth Today - Benzinga
Veeva Systems (NYSE:VEEV) Unveils Veeva AI To Boost Productivity In Life Sciences - Yahoo Finance
Werner Engelbrecht - AI Business
Veeva Systems (VEEV) Introduces Veeva AI to Enhance Life Science - GuruFocus
Veeva Systems Introduces Veeva AI - Contract Pharma
Announcing Veeva AI | VEEV Stock News - GuruFocus
Veeva Systems (VEEV) Introduces Veeva AI to Enhance Life Sciences Automation | VEEV Stock News - GuruFocus
Announcing Veeva AI - marketscreener.com
Veeva's Game-Changing AI Initiative Promises to Revolutionize Life Sciences Operations by 2025 - Stock Titan
Here's Why You Should Add Veeva Stock to Your Portfolio Now - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
Peering Into Veeva Systems's Recent Short Interest - Benzinga
Veeva (VEEV) Price Target Trimmed by Piper Sandler Amid Industry Challenges | VEEV Stock News - GuruFocus
Zacks Industry Outlook Highlights Veeva Systems, Hims & Hers Health and Butterfly Network - Yahoo Finance
Life Science Data Needs an Upgrade: Veeva Has Answers - Fierce Pharma
Here is What to Know Beyond Why Veeva Systems Inc. (VEEV) is a Trending Stock - MSN
Wall Street Bulls Look Optimistic About Veeva (VEEV): Should You Buy? - Yahoo Finance
Veeva Systems: Substantially Overvalued As Growth Slows (NYSE:VEEV) - Seeking Alpha
Veeva Systems (NYSE:VEEV) Partners With Flatiron To Enhance Clinical Trial Data Efficiency - Yahoo Finance
Flatiron Health Joins Veeva’s Product Partner Program to Accelerate Oncology Clinical Research - Business Wire
Q4 Earnings Outperformers: Veeva Systems (NYSE:VEEV) And The Rest Of The Vertical Software Stocks - Yahoo Finance
Veeva Systems (VEEV) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Veeva Systems’ chief customer officer sells $265,168 in stock By Investing.com - Investing.com India
Veeva Systems’ chief customer officer sells $265,168 in stock - Investing.com
4 Ways Top Sponsors Build Strong and Sustainable Site Relationships - Veeva
Investors Interested In Veeva Systems Inc.'s (NYSE:VEEV) Earnings - simplywall.st
Improve Safety Outputs, Oversight, and Data Quality with In-house Pharmacovigilance Solution - Veeva
B. Braun Transforms Global Clinical Trial Management for Digital Excellence - Veeva
Veeva (VEEV) Moves 3.7% Higher: Will This Strength Last? - Nasdaq
eClinical Solutions Market Top PlayersMedidata, Veeva Systems, Iqvia Inc., Icon Plc, Signant Health. - openPR.com
ACELYRIN Optimizes the Sponsor-CRO Data Flow with a Centralized Clinical Data Workbench - Veeva
Veeva Systems director Timothy Cabral sells $841,734 in stock By Investing.com - Investing.com Canada
Veeva Systems director Timothy Cabral sells $841,734 in stock - Investing.com
Veeva Systems (VEEV) Gains As Market Dips: What You Should Know - Yahoo Finance
Finanzdaten der Veeva Systems Inc-Aktie (VEEV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):